Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00710580

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Plaque Psoriasis Clinical Trial

Official title:
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Clinical Trial Summary

Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

  • Moderate to Severe Plaque Psoriasis
  • Psoriasis
Clinical Trial Details
NCT number NCT00710580
Study type Interventional
Source AbbVie
Contact
Status Completed
Phase Phase 3
Start date July 2008
Completion date April 2009
View Details
See also
  Status Clinical Trial Phase
Completed NCT05020249 - A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis Phase 3
Completed NCT01202565 - Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice N/A
Recruiting NCT05258331 - Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis Phase 1
Withdrawn NCT03146247 - Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients Phase 4
Recruiting NCT04367441 - Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects Phase 1
Completed NCT01644396 - An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Phase 4
Completed NCT01622348 - Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis Phase 2
Recruiting NCT04566666 - To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis Phase 2
Active, not recruiting NCT05155098 - 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
Recruiting NCT06425549 - A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis Phase 3
Completed NCT01555606 - An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis Phase 4
Completed NCT02713295 - A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece
Completed NCT05342428 - Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis Phase 1
Completed NCT04967508 - A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis Phase 3
Recruiting NCT06109818 - Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis Phase 2
Completed NCT01077232 - Documentation of Humira in Psoriasis Patients in Routine Clinical Practice
Completed NCT03412747 - A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 3
Withdrawn NCT04614298 - A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis Phase 4
Completed NCT02982005 - A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea Phase 3
Completed NCT00626002 - Open Label Continuation Study in Moderate to Severe Psoriasis Phase 3